A preliminary clinical investigation into the potential of blood lead levels to measure bone resorption in patients with skeletal metastases, using ICP-MS

Journal of Trace Elements in Medicine and Biology

Volumn 14, Issue 2, 2000, Pages 108-115

  Roberts, F J ^a   Ebdon, L ^b   Hill, S J ^b  

^a TORBAY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

Biochemical markers; Blood; Bone metastases; Bone resorption; ICP MS; Lead; Trace metals

Indexed keywords

BIOCHEMICAL MARKER; LEAD; NITRIC ACID; TRITON X 100;

ACCURACY; ANALYTIC METHOD; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; LEAD BLOOD LEVEL; MASS SPECTROMETRY; NUTRITION; OSTEOLYSIS; PRIORITY JOURNAL; QUALITY CONTROL;

EID: 0033943793     PISSN: 0946672X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0946-672X(00)80040-1     Document Type: Article

References (44)

1. BOLAND P.J., LANE J.M. AND SUNDARESAN N. Metastic discase of the spine. Clin. Chem. 1982; 169: 98-102.
2. BLOMQVIST C., ELOMAA I., VIRKKUNEN P., PORKKA L., KARONEN S.L., RISTELI L. AND RISTELI J. The response evaluation of bone metastases in mammary carcinoma: The value of radiology, scintigraphy and biochemical markers of bone metabolism. Cancer 1987; 60: 2907-2912.
3. COLEMAN R.E., MASHITER G. FOGELMAN I., WHITTAKER K.D., CALEFFI M., MOSS D.W., AND RUBENS R.D. Bone scan flare predicts successful system therapy for bone metastases. Eur. J. Cancer Clin. Oncol. 1988; 24: 1211-1217.
4. SEIBEL M.J., ROBINS S.P. AND BILEZIKIAN J.P. Urinary pyridinium crosslinks of collagen. Specific marker of hone resorption in metabolic bone disease. Trends Endocrinol. Metab. 1992; 3: 263-270.
5. PATERSON C.R., ROBINS S.P., HOROBIN J.M., PREECE P.E. AND CUSCHIERI A. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br. J. Cancer 1991; 64: 884-886.
6. COLEMAN R.E., HOUSTON S., JAMES I., RODGER A., RUBENS R.D., LEONARD R.C.F. AND FORD J. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastic bone disease. Br. J. Cancer 1992; 65: 766-768.
7. BODY J.J. AND DELMAS P.D. Urinary pyridinium crosslinks as markers of bone resorption in tumour-associated hypercalcemia. J. Clin. Endocrinol. Metab. 1992; 74: 471-475.
8. LIPTON A., DEMERS L., DANILOFF Y., CURLEY E., HAMILTON C., HARVEY H., WITTERS L. SEAMAN J. VAN DE GIESSEN R. AND SEYEDIN S. Increased urinary excretion of pyridinium crosslinks in cancer patients. Clin. Chem. 1993; 39: 614-618.
9. MIYAMOTO K.K., MCSHERRY S.A., ROBINS S.P., BESTERMAN J.M. AND MOHLER J.L. Collagen crosslink metabolites in urine as markers of bone metastases in prostate carcinoma. J. Urology 1994; 151: 909-913.
10. SANO M., KUSHIDA K., TAKAHASHI M., OHISHI T., KAWANA K., OKADA M. AND INOUE T. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastases. Br. J. Cancer 1994; 70: 701-703.
11. PERCHERSTORFER M., ZIMMER-ROTH I., SCHILLING T., WOITGE H.W., SCHMIDT H., BAUMGARTNER G., THEIBAUD D., LUDWIG H., AND SEIBEL M.J. The diagnostic-value of urinary pyridinium crosslinks of collagen, serum total alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J. Clin. Endocrinol. Metab. 1995; 80: 97-103.
12. COLWELL A, RUSSELL R.G.G. AND EASTELL R. Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur. J. Clin. Invest. 1993; 23: 341-349.
13. SEYEDIN S.M., KUNG V.T., DANILOFF Y.N., HESLEY R.P., GOMEZ B., NIELSON L.A., ROSEN H.N. AND ZUK R.F. Immunoassay for urinary pyridinoline: The new marker of bone resorption. J. Bone Miner. Res. 1993; 8: 635-641.
14. ROBINS S.P., WOITGE H., HESLEY R., JU L., SEYEDIN S. AND SEIBEL M.J. Direct, enzyme linked immunoussay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J. Bone Miner. Res. 1994; 9: 1643-1649.
15. KNIEWALD G., KOZAR S., BRAJKOVIC D., BAGI C. AND BRAICA M. Trace metal levels in fossil human bone from the Bezdanjaca necropolis in Croatia. Sci. Total Environ. 1994; 151: 71-76.
16. LINDH U. A nuclear microbe investigation of heavy metal distribution in individual osteons of human femur. Int. J. Appl. Radiat. Isotopes 1980; 31: 737-746.
17. SKERFING S. AND NILSSON U. Assessment of accumulated body burden of metals. Toxicol. Lett. 1992; 64/65: 17-24.
18. O'CONNER B.H., KERRIGAN G.C., TAYLOR K.R., MORRIS P.D. AND WRIGHT C.R. Levels and temporal trends of trace element concentrations in vertebral bone. Arch. Environ. Health 1988; 35: 21-28.
19. MILACHOWSKI K.A. Investigations of ischaemic necrosis of the femoral head with trace elements. Int. Orthop. 1988; 12: 323-330.
20. ZAICHICK V.Y. Instrumental activation and x-ray fluorescent analysis of human bone in health and disease. Nucl. Chem. 1994; 179: 295-303.
21. ROBERTS N.B., WALSH H.P.J., KLENERMAN L., KELLY S.A. AND HALLIWELL T.R. Determination of elements in human femoral bone using inductively coupled plasma atomic emission spectrometry and inductively coupled plasma mass spectrometry. J. Anal. At. Spectrom. 1996; 11: 133-138.
22. VAN DAELA P.L.A., BIRKENHAGER J.C. AND POLS H.A.P. Biochemical markers of bone turnover: an update. Neth. J. Med., 44: 65-72.
23. BARRY P.S. A comparison of concentrations of lead in human tissues. Br. J. Ind. Med. 1975; 32: 119-139.
24. CORY-SLECHTA D.A. Lead exposure during advanced age: Alterations in kinetics and biochemical effects. Toxicol. Appl. Pharmacol. 1990; 104: 67-78.
25. NILSSON U., ATTWELL R., CHRISTOFFERSSON J.O., SCHUTZ A., AHLGREN L., SKERFING S. AND MATTSON S. Kinetics of lead in bone and blood after end of occupational exposure. Pharmacol. Toxicol. 1991; 68: 477-484.
26. BROWN A. AND TOMPSETT S.L. Poisoning due to mobilisation of lead from the skeleton by leukaemic infiltration of bone marrow. Br. Med. J. 1945; 2: 764-765.
27. BROWN A. The lead content of the blood and its distribution to rarefying processes in bone. Quart. J. Med. 1946; 39: 77-79.
28. KIJEWSKI H. AND LOWITZ H.D. The estimation of lead in hydride form from biopsy specimens from the iliac crest of patients who had contracted lead poisoning many years previously. Arch. Toxicol. 1982; 50: 301-311.
29. MARKOWITZ M.E AND WIENBERGER H.L. Immobilisation related lead toxicity in previously lead poisoned children. Paediatrics 1990; 86: 455-457.
30. THOMPSON G.N. ROBERTSON E.F AND FITZGERALD S. Lead mobilisation during pregnancy. Med. J. Aust. 1985; 143:131.
31. BORUTHON-KOPP C., HULL G. AND GRASMICK C. Effects of pregnancy on inter-individual variation blood levels of lead, cadmium and mercury. Biol. Res. Pregnancy 1986; 7:37-42.
32. MANTON WI. Total contribution of airborne lead to blood lead. Br. J. Ind. Med. 1985; 42: 168-172.
33. SILBERGELD E.K., SCHWARTZ J. AND MAHAFFEY K. Lead and osteoporosis - mobilisation of lead from bone in postmenopausal woman. Environ. Res. 1988; 47: 79-94.
34. EL-SHARKAWI A.M., COBBOLD S., EVANS C.J., CHETTLE D.R., MORGAN W.D., JAIB M.B.M., SOMERVAILLE L.J. AND SCOTT M.C. Unexpected mobilisation of lead during cisplatin chemotherapy. Lancet 1986; ii: 249-250.
35. EVETTS I., MILTON D. AND MASON R. Trace element analysis in body fluids by glow discharge spectrometry: A study of lead mobilisation by the drug cisplatin. Biol. Mass Spectrom. 1991; 20: 153-159.
36. TODD A.C., CHETTLE D.R., SCOTT M.C., SOMERVAILLE L.J., BRAITHWAITE R.A., BEANEY R.P. AND BUXTON E.J. A pilot study using 99Tc to measure lead and platinum in the human kidney. Nucl. Med. Biol. 1993; 20: 589-595.
37. EVETTS I., STEDMAN G., MASON R.S., EL-SHARKAWI A., EVANS C.J. AND DUTTON J. Further observations on lead mobilisation by cisplatin. Basic Life Sci. 1993; 60: 311-314.
38. SUBRAMANIAN KS. Determination of trace metals in human blood by graphite furnace atomic absorption spectrometry. Prog Analyt. Spectrosc. 1986; 9: 237-334.
39. COSTANTINI S., GIORDANO R. AND RUBBIANI M. Comparison of flameless atomic absorption spectrometry anodic stripping voltammetry for the determination of lead. Microchem. J. 1987; 35: 70-82.
40. NAVARRO J.A., GRANADILO V.A. AND ROMERO R.A. Determination of lead in whole blood by graphite furnace atomic absorption spectrometry with matrix modification. J. Anal. At. Spectrom. 1989; 4: 401-406.
41. TAHAN J.E., GRANADILO V.A. AND ROMERO R.A. Electrothermal atomic absorption spectrometric determination of Al, Cu, Fe, Pb, V and Zn in clinical samples and in certified environmental reference materials. Anal. Chim. Acta 1994; 295: 187-197.
42. GRANADILO V.A. AND ROMEREO R.A. Graphite furnace atomisation behaviour of lead contained in chemical and environmental materials in the presence of palladium induced isoformation and citric acid. J. Anal. At. Spectrom. 1993; 8: 615-622.
43. NUTTALL K.L., GORDEN W.H. AND ASH K.O. Whole blood lead reference intervals for adults. Clin. Chem. 1993; 39: 1349-50.
44. RABINOWITZ MB. Toxicokinetics of bone lead. Environ. Health Perspect. 1991; 91: 33-37.